Compare ADMA Biologics Inc (ADMA) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Exxon Mobil Corporation — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Exxon Mobil Corporation trades at $140.6 (market cap $587.30B). The key difference: Exxon Mobil Corporation is far larger — about 275.7× ADMA Biologics Inc's market cap, and Exxon Mobil Corporation pays a 2.91% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | XOM | |
|---|---|---|
Market Cap | $2.13B | $587.30B |
Sector | Health | Energy |
52-Week High | $20.38 | $171.52 |
52-Week Low | $7.60 | $105.83 |
Enterprise Value | $2.20B | $626.52B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ExxonMobil (XOM) trades at $136.44, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong operational cash flow of $52.0B in 2025 and a healthy balance sheet with 15.44% debt-to-capitalization. Recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $150-160 per barrel amid Middle East tensions.
XOM presents a mixed outlook with attractive valuation metrics (P/E 22.97, below energy sector average) and analyst consensus target of $172.79 (26% upside). However, declining revenue trends ($323.9B in 2025 vs. $398.7B in 2022) and bearish technical indicators suggest near-term headwinds. The stock offers income potential with recent $1.03 dividend but faces oil price volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
